Bone system disease therapeutic agent and its applications

Bone dysplasias caused by excessive activation of FGFR3, particularly, for achondroplasia and cartilage hypoplasia, and to provide a novel treatment strategy with excellent therapeutic effects. Containing as meclizine or an active ingredient a pharmaceutically acceptable salt thereof, a therapeutic agent for bone lineage disease.